|Articles|October 31, 2022
Massive Bio Onboards Over 100,000 Cancer Patients
Advertisement
Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.
Read more about the platform and its enrollment
.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The AI Churn Trap in Life Sciences and How to Break It
2
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
3
Real-World Evidence in Transition: CRO Adaptation to the European Health Data Space Framework
4
Workflow in the Age of AI
5